일본의 혈관 접근 기기 시장 규모는 2026-2033년의 예측 기간 동안 6.14%의 연평균 복합 성장률(CAGR)로 확대되어 2025년 3억 8,844만 달러에서 2033년에는 5억 8,942만 달러로 성장할 것으로 예상됩니다. 일본의 혈관 접근 기기 시장은 암, 신장 질환과 같은 만성 질환의 유병률 증가로 인해 일본 의료 환경 전반에서 혈관 접근 기기의 사용이 증가함에 따라 크게 성장하고 있습니다. 정부의 의료 개혁과 병원 인프라 개선은 첨단 혈관 기술의 채택을 더욱 촉진하고 있습니다. 또한, 국내 제조업체들이 안전 설계의 감염 방지 카테터에 집중하면서 급성기 의료 및 장기 요양 환경 모두에서 시장 성장이 가속화되고 있습니다.
예를 들어, 일본 후생노동성은 2024년 12월 1일 DVT용 혈전제거 시스템 '클로토트리버'의 보험급여를 승인했습니다. 이는 일본 의약품의료기기종합기구(PMDA)가 2023년 12월 클로토트리버 시스템을 승인한 이후 나온 것입니다. 후생노동성은 클로토트리버의 특수한 작용기전으로 인해 DVT 환자에서 벽에서 벽까지 완전히 혈전을 제거할 수 있어 기존 카테터를 이용한 치료법과는 다른 새로운 기능 구분을 설정했습니다.
일본의 혈관 접근 기기(Vascular Access Device) 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별, 용도별, 최종사용자별, 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.
Japan vascular access devices market is projected to witness a CAGR of 6.14% during the forecast period FY2026-FY2033, growing from USD 388.44 million in FY2025 to USD 589.42 million in FY2033. Japan market for dermal fillers has grown significantly due to rising prevalence of chronic conditions such as cancer and renal disease is prompting increased use of vascular access devices across Japanese healthcare settings. Government healthcare reforms and hospital infrastructure upgrades are further facilitating the adoption of advanced vascular technologies. Additionally, local manufacturers' focus on safety-engineered, infection-resistant catheters is accelerating market growth in both acute and long-term care environments.
For example, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the ClotTriever Thrombectomy System for DVT for national reimbursement on December 1, 2024, according to a statement released today by Inari Medical, Inc., a medical device company dedicated to treating and improving the lives of patients with venous and other vascular diseases. This statement comes after the Pharmaceuticals and Medical Devices Agency (PMDA) approved the ClotTriever system in December 2023. MHLW established a new functional category distinct from previous catheter-based therapies because of ClotTriever's special mode of action for total, wall-to-wall thrombus elimination in patients with DVT.
Rising Geriatric Population and Prevalence of Chronic Conditions Driving Market Growth
Japan has one of the highest proportions of elderly individuals globally, with more than 29% of its population aged 65 or older. This aging demographic is more susceptible to chronic diseases such as cardiovascular disorders, diabetes, and cancer, which often require repeated intravenous treatments, thereby boosting the demand for vascular access devices. The increase in long-term hospital stays and the need for regular drug or fluid administration further propel the market. Additionally, age-related complications increase the likelihood of conditions like kidney failure, which often require dialysis through central vascular access. These factors collectively support the growing adoption of vascular access devices in Japan's healthcare system. For instance, according to Japan's Ministry of Internal Affairs and Communications, as of 2023, seniors (65+) made up 29.1% of the total population, highlighting the pressing need for chronic disease management solutions.
Technological Advancements and Focus on Infection Control in Hospitals Fueling Growth
Japanese healthcare facilities are placing greater emphasis on adopting technologically advanced vascular access devices that minimize infection risk and improve efficiency. Innovations in catheter coatings, antimicrobial materials, and securement devices have significantly reduced complications such as catheter-related bloodstream infections (CRBSIs). Japan's hospitals, known for their high standards of care and patient safety, are actively integrating smart vascular access technologies, such as ultrasound-guided placement and needle-free connectors, to enhance clinical outcomes. Moreover, post-pandemic hygiene awareness has accelerated the shift toward disposable and safer vascular access solutions. These trends are boosting the penetration of vascular access devices in both public and private healthcare settings. For example, in April 2024, Nipro partnered with Haselmeier to introduce the PiccoJect, a patient-centric autoinjector designed for 1 mL long and 2.25 mL, pre-filled syringes. The device was showcased at CPHI Japan in Tokyo, which marks Nipro's commitment to innovative drug delivery solutions.
Increasing Demand for Peripheral Vascular Access Devices for Short-Term Use
Peripheral vascular access devices are witnessing a significant rise in adoption across Japan due to their widespread use in short-term therapies such as drug infusions, fluid administration, and nutritional support. These devices, including peripheral intravenous (PIV) catheters, are easy to insert, cost-effective, and less invasive compared to central vascular access devices, making them ideal for outpatient departments, emergency care, and routine medical interventions. The increasing number of outpatient surgeries, homecare treatments, and emergency admissions in Japan's aging healthcare infrastructure is supporting the demand for these products. Additionally, patient preference for minimally invasive and shorter treatment durations aligns with the utility of peripheral devices. Healthcare providers in Japan are also investing in newer-generation safety-engineered PIV catheters that minimize needlestick injuries and infection risks, enhancing procedural outcomes and staff safety. These developments are collectively contributing to the growing adoption of peripheral vascular access devices in Japan's evolving clinical care landscape. In March 2024, B. Braun Aesculap Japan introduced "Introcan Safety(R) 2 IV Catheter," which features enhanced safety mechanisms to reduce needlestick injuries and is tailored for peripheral access in short-term treatments.
Future Market Scenario (FY2026 - FY2033F)
The Japan vascular access devices market is poised for steady growth in the coming years, driven by an aging population, rising chronic disease burden, and an evolving healthcare system that emphasizes minimally invasive treatments. As hospitals and clinics increasingly adopt advanced vascular access technologies to reduce infection risks and improve patient outcomes, demand for both central and peripheral access devices is expected to rise. The market is also likely to benefit from local innovation, government support for digital healthcare, and a growing preference for home-based care. Continuous R&D and product upgrades will further enhance market penetration across urban and rural settings.
Key Players Landscape and Outlook
Key players in the vascular access devices industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For instance, In January 2025, Nipro announced the international sales launch of the DIAMAX WOW Single Patient Dialysis Machines. This product introduction shows Nipro's dedication for advancing the dialysis technology and improving patient care.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.